We were delighted to have the honour of speaking to Jeffrey Cohen (Cleveland Clinic, Cleveland, OH, USA), the president of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). He shared positive findings and expert insight from the phase 3 INROADS study, which investigated the safety and efficacy of amantadine extended release capsules in patients with multiple sclerosis with walking impairment (ClinicalTrials.gov identifier: NCT03436199). This discussion was based on his MSVirtual2020 presentation: P0225 – Phase 3 Study Results Assessing the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in MS Patients with Walking Impairment.
1. What are the limitations of current therapies for walking impairment in people with multiple sclerosis (MS)? (0:06)
2. What is the rationale for the use of amantadine in patients with MS and walking impairment? (0:51)
3. Could you tell us a little about the pharmacokinetics of ADS-5102 and its advantages over immediate release formulations of amantadine in MS therapy? (1:24)
4. Could you give us an overview of the INROADS study and its major findings? (2:12)
5. What are the clinical implications of these findings and what future studies are planned? (3:18)
Disclosures: Dr Cohen reports receiving personal compensation for consulting for Adamas, Atara, Bristol-Myers Squibb, Convelo, MedDay, and Mylan; and serving as an Editor of Multiple Sclerosis Journal.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!